{
  "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe",
  "docSlug": "303c45082bb692ab214f73eda43168dc",
  "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 30,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/18",
  "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe",
  "deckJsonHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe.json",
  "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.7,
        "y": 0.28
      },
      "kind": "chart",
      "text": "NAFLD Activity Score",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49647366-9b9a-400f-8f15-20e28945e850",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.7,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Liver Triglycerides",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b00e46ab-5265-4f11-9d39-cbeedb3a78e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.4,
        "y": 0.32
      },
      "kind": "diagram",
      "text": "5-week C57BL/6 Mouse -> 30-week GAND Feeding -> 9-Week s.c. Injection",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b17b40a-e70f-40b5-9751-caadfdf5aba8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.65,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "image",
      "text": "Histology images for Steatosis/Inflammation and Fibrosis",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdb34ecd-43ad-486f-baa8-d14a1a62122f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "list",
      "text": "Animals: male DIO-NASH mice; Regimen: Every three days S.C. injection; Dose: 100 & 200 nmol/kg DA-1726 vs. 250 nmol/kg semaglutide",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb102261-d21a-49f7-82a4-6025878f2e25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "NASH (Non-Alcoholic Steatohepatitis); DIO (Diet Induced Obesity); S.C. (Subcutaneous); NAFLD (Non-Alcoholic Fatty Liver Disease); HE (Hematoxylin and Eosin); MT (Masson's Trichrome). Dong-A Study Report 104854. Jung IH et al. 82nd Meeting of the American Diabetes Association. 2022; Abstract 1333-P.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08dea922-3d11-49f1-a9f5-f3c0e6d1939c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "title",
      "text": "DA-1726 further improved hepatic steatosis, inflammation, and fibrosis compared to semaglutide",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d6bc7f5-5429-401b-b7fe-bfd8334902eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "DA-1726 Therapeutic Potential for NASH (1,2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfc94394-5550-49e1-aed5-4924552b03c9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "dd1e7938-8c0b-447f-aed7-231987ef7619",
      "evidence": "The table structure suggests a possible 2x2 matrix, but it's not explicitly clear.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 8,
      "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents DA-1241 and DA-1726 as potential solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 20,
      "from": 9,
      "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 8,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d",
      "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential",
      "position": 1,
      "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}